Literature DB >> 20811701

Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas.

Junichiro Tanaka1, Kazushi Sugimoto, Katsuya Shiraki, Masahiko Tameda, Satoko Kusagawa, Keiichiro Nojiri, Tetsuya Beppu, Kentaro Yoneda, Norihiko Yamamoto, Kazuhiko Uchida, Takahiro Kojima, Yoshiyuki Takei.   

Abstract

Toll-like receptor 9 (TLR9) is a pattern-recognition receptor that is involved in immune signaling and plays a crucial role in cell survival through recognition of various bacterial and viral components including unmethylated CpG-DNA. TLR9 expression and function in cancer cells are not well understood. We investigated the expression of TLR9, and the function of TLR9 signaling, in hepatocellular carcinoma (HCC) cells following stimulation with CpG-oligodeoxynucleotides (ODNs). Positive immunohistochemical staining for TLR9 was observed in 85.7% of HCC tissues. Western blot analysis revealed that TLR9 was expressed both on the cell membrane and in the cytoplasm of HCC cell lines. Full-length TLR9 was predominantly expressed on the membrane rather than in the cytoplasm, whereas multiple cleaved forms of TLR9 were predominantly expressed in the cytoplasm rather than on the membrane. Cell surface stimulation of TLR9 promoted cell proliferation, and, furthermore, the TLR9 agonists, CpG-ODNs, reduced the cytotoxicity of the anti-cancer drug adriamycin (ADM) via up-regulation of apoptosis inhibitors such as survivin, Bcl-xL, XIAP and cFLIP, in HCC cell lines. Although cell surface stimulation of TLR9 did not activate either the NF-kappaB signaling pathway or the type-I IFN secretion pathway, gene chip microarray analysis indicated that TLR9 agonists closely regulated multiple oncology-related genes and transcription factors involved in tumorigenesis and cancer progression. In conclusion, our results indicate that functional cell surface expression of TLR9 in human HCC may play an important role in tumorigenesis and cancer progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811701

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  27 in total

Review 1.  Mucins and toll-like receptors: kith and kin in infection and cancer.

Authors:  Shikha Tarang; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-02-03       Impact factor: 8.679

2.  Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9.

Authors:  Yao Liu; Wei Yan; Samer Tohme; Man Chen; Yu Fu; Dean Tian; Michael Lotze; Daolin Tang; Allan Tsung
Journal:  J Hepatol       Date:  2015-02-12       Impact factor: 25.083

3.  The contribution of toll-like receptor signaling to the development of liver fibrosis and cancer in hepatocyte-specific TAK1-deleted mice.

Authors:  Isabelle Jingyi Song; Yoon Mee Yang; Sayaka Inokuchi-Shimizu; Yoon Seok Roh; Ling Yang; Ekihiro Seki
Journal:  Int J Cancer       Date:  2017-09-23       Impact factor: 7.396

Review 4.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

5.  Toll-like receptor signaling in liver regeneration, fibrosis and carcinogenesis.

Authors:  Ekihiro Seki; Eekjoong Park; Jiro Fujimoto
Journal:  Hepatol Res       Date:  2011-06-22       Impact factor: 4.288

Review 6.  Immunobiology of hepatocellular carcinoma.

Authors:  Tobias Flecken; Hans Christian Spangenberg; Robert Thimme
Journal:  Langenbecks Arch Surg       Date:  2011-04-09       Impact factor: 3.445

Review 7.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

Review 8.  Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?

Authors:  Jorge André Gomes Lopes; Marta Borges-Canha; Pedro Pimentel-Nunes
Journal:  World J Hepatol       Date:  2016-01-28

9.  Targeting Toll-Like Receptors for Cancer Therapy.

Authors:  Marc J Braunstein; John Kucharczyk; Sylvia Adams
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

10.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.